Skip to content Skip to footer
Close
Keep Updated

News

Stay informed about Toxnet efforts to lead education, clinical innovation, and research in spasticity, and related disorders, aiming to inspire and guide clinicians for the ultimate benefit of their patients.

This section provides the latest updates from Toxnet about new publications, past and upcoming events, progress on our innovative and educational initiatives, and developments in our research programme.

GO-FAST 2.0 launched at Toxins Congress

GO-FAST 2.0, the updated digital tool developed by Toxnet to support the assessment and management of focal spasticity, was launched at the recent Toxins Congress.

23 January 2026

Toxnet meeting 17-18 October 2025

The Toxnet group held their second biannual meeting of 2025 in Seville, Spain. The group visited the Hospital Universitario Juan Ramón Jiménez, Huelva where they discussed some innovative interventional techniques for spasticity management and pain associated to spasticity and then worked together to progress the Toxnet group initiatives.

19 October 2025

Toxnet Award

The Toxnet award for 2026 is now closed. The winner will be announced during the ISPRM meeting in Vancouver in May 2026.

6 June 2025

‘Clinical Pearl’ article accepted for publication.​

The Clinical Pearl article, ‘How I would treat spastic clenched fist deformity in a stroke patient’ has just been accepted for publication by The Journal of the International Society of Physical and Rehabilitation Medicine. In this article Steven Escaldi and Djamel Bensmail discuss how they would treat this hypothetical case and Monica Gutierrez Verduzco provides a commentary on their contrasting approaches.

6 May 2025

Toxnet meeting 4-5 April 2025​

The Toxnet group recently held their first biannual meeting of 2025 in Copenhagen, Denmark. The group visited the University of Copenhagen where they discussed how to treat Complex Regional Pain Syndrome and then worked together to progress the Toxnet group initiatives.

4 April 2025

© 2026 ToxNet. All Rights Reserved.

Supported by Merz Therapeutics GmbH

Liability for links
Our site contains links to external websites, over which we have no control. Therefore we cannot accept any responsibility for this external content. The respective provider or operator is always responsible for the contents of any linked site. At the time of linking the linked sites where checked for possible legal violations. At the time of linking illegal contents were not indicated. A permanent control of the linked pages is unreasonable without concrete evidence of violation. Upon notification of violations, we will remove such links immediately.

Award scoring criteria

The following criteria will be judged out of a score of 5; (1 is suboptimal; 2 is adequate; 3 is good; 4 is very good; 5 is excellent)

GENERAL

  • Days per week working in spasticity management
  • Average number of unique spasticity patient encounters per month (by the individual)
  • Description of spasticity clinical team & management activities and (numbers, specialities etc)
  • Role of responsibility in managing patients with spasticity
  • Scientific appointments in spasticity
  • Honours for work undertaken in spasticity

SCHOLARLY

  • Number of research projects investigating relevant aspects of spasticity management (involvement)
  • Impact of research projects investigating relevant aspects of spasticity management
  • Number of peer-reviewed publications on topic
    Number of presentations of research at international meetings
  • Number of posters/presentations at local and national conferences
  • Teaching/mentorship of younger injectors
  • h-index

CLINICAL

  • Evidence of development or growth of a spasticity program at the applicant’s practice or institution
  • Breadth of services provided, including medications, toxins, physical interventions, and Intrathecal Baclofen Therapy (ITB)
  • Role of responsibility in managing patients with spasticity

ENDORSEMENT

  • Endorsed by senior peer

In the event of a tie, based on the above scoring criteria, the Toxnet Co-Chairs will make the final decision.